Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28869955 | 0.93 | CA12 (0.56) | LMNAKMT2AL3MBTL1ALDH1A1POLB | |
| SCHEMBL6900910 | 0.88 | CA12 (0.53) | KMT2AL3MBTL1ALDH1A1CA12CA1 | |
| SCHEMBL3149772 | 0.86 | CA12 (0.44) | LMNAKMT2APOLBCA12CA1 | |
| SCHEMBL4992625 | 0.84 | KDM4E (0.44) | LMNAKMT2AL3MBTL1POLBCA12 | |
| SCHEMBL5007630 | 0.83 | L3MBTL1 (0.50) | LMNAKMT2AL3MBTL1ALDH1A1POLB | |
| SCHEMBL8262562 | 0.83 | KMT2A (0.50) | LMNAKMT2AL3MBTL1ALDH1A1POLB | |
| SCHEMBL3116291 | 0.83 | KMT2A (0.58) | KMT2APOLBCA12CA1CA2 | |
| SCHEMBL21543727 | 0.82 | HCRTR1 (0.51) | LMNAKMT2AL3MBTL1ALDH1A1CA12 | |
| SCHEMBL19064581 | 0.82 | CA12 (0.67) | LMNAKMT2AL3MBTL1ALDH1A1CA12 | |
| SCHEMBL9410550 | 0.82 | L3MBTL1 (0.47) | LMNAKMT2AL3MBTL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3551625-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885KMT2A 3137/4885L3MBTL1 4608/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885KMT2A 3137/4885L3MBTL1 4608/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885KMT2A 3137/4885L3MBTL1 4608/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885KMT2A 3137/4885L3MBTL1 4608/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885KMT2A 3137/4885L3MBTL1 4608/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | LMNA 1910/4885KMT2A 1250/4885L3MBTL1 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.